Celyad Oncology SA (EBR:CYAD)

Market Cap	13.43M -28.0%
Revenue (ttm)	21.00K -88.7%
Net Income	830.00K
EPS	0.02
Shares Out	44.76M
PE Ratio	16.67
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,602
Average Volume	14,005
Open	0.2880
Previous Close	0.3000
Day's Range	0.2870 - 0.2980
52-Week Range	0.1600 - 0.6500
Beta	1.19
RSI	47.40
Earnings Date	Sep 23, 2026

About Celyad Oncology

Celyad Oncology SA, a biotechnology company, focuses on unlocking the potential of its intellectual property. Its portfolio comprises multiple foundational US patents focused on TCR-deficient T cell compositions, and it broadly covers allogeneic CAR T cell therapies. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 5
• Stock Exchange: Euronext Brussels
• Ticker Symbol: CYAD